Kornimate/medical-research-clean huggingface dataset:
long-term surgical therapeutic outcomes of peri-implantitis

Conditions: Peri-Implantitis

Summary: this study focuses on evaluating the success of different treatment methods for peri-implantitis (gum disease around implants) and to understand the factors that might affect the success of the treatment provided.

qualifying patients will be asked to participate in clinical measurements to compare the long-term success of their treatments. the aims of the current study are to 1) assess the long-term outcome of the surgical treatment of peri-implantitis and to 2) evaluate the success of the different treatment modalities of peri-implantitis.

Eligibility criteria:
inclusion criteria: 1. the patient is at least 18 years of age, 2. was initially diagnosed with peri-implantitis at ≥1 implant (peri-implant probing depth (ppd) ≥ 6 mm together with bleeding and/or suppuration on probing (bop/sop) and radiologically assessed marginal bone loss ≥ 3 mm), 3. had received treatment for peri-implantitis at least 5 years ago at the graduate clinic of periodontics at university of michigan, and 4. documentation from ≥ 5 years of clinical and radiological follow-up is available from u of m patients records. exclusion criteria: 1. has received or is currently receiving radiotherapy, 2. are currently pregnant, unsure of their pregnancy status, or are lactating (as reported by the patient), 3. has health condition(s) or takes medication(s) that are known to affect soft tissue or bone (e.g., phenytoin)
a retrospective and prospective natural history of genetic vasculopathies

Conditions: Multisystemic Smooth Muscle Dysfunction Syndrome; ACTA2

Summary: this study will combine retrospective review of medical records from patients with acta2 and ongoing collection of clinical data using standardized instruments and intervals on an observational basis from patients with acta2. patients in cohorts 1-3 will be asked to attend clinic visits in person per the schedule of events. at minimum, the medical records of patients with acta2 will be reviewed to record data on aspects of the disease, including disease characteristics and developmental milestones. the study is planned to enroll a total of 100 patients: 7 in cohort 1, 7 in cohort 2, and the remaining in cohorts 3 and 4. this study is planned to study patients for at least 3 years with the option to continue as long as possible for assessment of disease progression. during their continued study participation, as patients age, they may move into the next cohort. beyond 3 years the duration of the study with be determined by availability of funding from sponsors.


Eligibility criteria:
inclusion criteria: * confirmed acta2 pathogenic variant * available medical records since birth that permit documentation of disease characteristics and developmental milestone * have two parents and/or legal guardians who are english speaking and are able to read, understand, and sign the informed consent * able to tolerate travel to study site exclusion criteria: * patient does not meet the inclusion criteria * patient is currently pregnant
clinical validation of propecg-tmt

Conditions: Coronary Artery Disease

Summary: this clinical validation evaluates the performances of physicians with and without learning with propecg-tmt assistance for screening coronary artery revascularization on tmt-ecg. there are two endpoints used to evaluate performances: accuracy (primary endpoints with pair specificity/sensitivity, and ppv/npv), and time needed for screening (secondary endpoints with time measurements in all cases).


Eligibility criteria:
inclusion criteria: * tmt ecg exams adjudicated as equivocal cases exclusion criteria: * exams not converting to median beat ecg * exams not containing interpretable exercise
multiparametric cardio-hepatic mri in patients with noncirrhotic portal hypertension

Conditions: Hypertension, Portal; Cardiomyopathies

Summary: the aim of this study is to use multiparametric mri to investigate any differences in myocardial structure and function in patients with noncirrhotic portal hypertension compared with a control group with liver cirrhosis.

the term "cirrhotic cardiomyopathy" (ccm) was defined in 2005 according to expert consensus at the "world congress of gastroenterology" in montreal as a clinical phenotype in patients with liver cirrhosis consisting of systolic and diastolic dysfunction and a complementary criterion, such as electrophysiological changes, without the presence of a known underlying cardiac disease. for a long time, ccm was considered to result from toxic effects of alcohol consumption. the current view is that ccm is a separate entity independent of the various etiologies of liver cirrhosis. thus, generally impaired liver function and portal hypertension with splanchnic vasodilation leads to altered hemodynamic conditions with central hypovolemia, increased activation of volume and baroreceptors, especially of the sympathetic nervous system, resulting in a "hyperdynamic syndrome" with increased cardiac stress. however, the contribution of portal hypertension to ccm is unclear. with new mri techniques such as cardiac t1 and t2 mapping and extracellular volume fraction (ecv), quantitative parameters are available to detect pathologies of the myocardium before they become detectable with conventional techniques in cardiac mri or echocardiography. the aim of this study is to use multiparametric mri to investigate any differences in myocardial structure and function in patients with noncirrhotic portal hypertension compared with a control group with liver cirrhosis and to investigate a quantifiable correlation between cardiac, hepatic, and splenic parameters.

Eligibility criteria:
inclusion criteria: 1. noncirrhotic portal hypertension 2. age at least 18 years exclusion criteria: 1. underlying cardiac disease, e.g., coronary heart disease/myocardial infarction, myocarditis, cardiomyopathies of other causes, congenital heart disease 2. patients who are using a intrauterinpessare for contraception 3. pregnant and breastfeeding women 4. patients with contraindications for mri (not suitebale metallic implants) 5. patients with contraindications for mri contrast agents (renal insufficiency, allergy)

Keywords: cardiac mri hepatic mri
the effect of cycled light on premature infants and mothers

Conditions: Preterm Infant Development; Retinopathy of Prematurity; Sleep Quality; Quality of Life

Summary: irregular lighting and lack of light in premature infants will affect their health, produce negative effects such as physiological and visual development, and also affect the mother's sleep and quality of life. this study is to verify the effect and delay effect of two-week premature infants' light intervention on their physiological indicators and visual development, mother's sleep quality and quality of life. it is planned to be in the neonatal moderate to severe ward of national taiwan university children's hospital, and the subjects are premature babies born 32 weeks old. divided into two groups of light intervention group and control group, longitudinal tracking intervention effect and six-week and three-month delay effect.

background dim, irregular lighting and lack of periodic light in the care environment for premature babies in taiwan are currently common conditions. irregular lighting and lack of light in premature infants will affect their health, produce negative effects such as physiological and visual development, and also affect the mother's sleep and quality of life. purpose to verify the effect and delay effect of two-week premature infants' light intervention on their physiological indicators and visual development, mother's sleep quality and quality of life. methods the preliminary plan of this study is to carry out empirical evidence and expert advice to confirm precise lighting and develop care intervention strategies for preterm infants based on evidence. it is planned to be in the neonatal moderate to severe ward of national taiwan university children's hospital, and the subjects are premature babies born 32 weeks old. divided into two groups of light intervention group and control group, longitudinal tracking intervention effect and six-week and three-month delay effect.

Eligibility criteria:
inclusion criteria: (1) premature infants over 32 weeks old, (2) stable physiological conditions. exclusion criteria: (1) taking drugs that may interfere with sleep, (2) suffering from retinopathy (rop) stage 3 or higher, (3) suffering from intracranial hemorrhage, grade 3 or higher, (4) suffering from upper limb injury or movement disorders, (5) the family has alcohol and drug abuse problems, (6) currently using respirators.

Keywords: cycled light retinopathy of prematurity
thromboprophylaxis and bariatric surgery

Conditions: Thromboembolism

Summary: this trial is an assessment of the efficacy of three thromboprophylaxis regimens in two types of bariatric surgery. - gastric banding and gastric bypass on anti-xa activity levels the study includes two groups of 150 patients scheduled for gastric banding or gastric bypass. assessment of anti-xa levels before and 4 hours after the injections from day 0 to 2 in order to determine the best prophylactic regimen allowing expected values ranged between 0.3 and 0.5 iu / ml.


Eligibility criteria:
inclusion criteria: * bmi over 40 * gastric banding or gastric bypass exclusion criteria: * renal insufficiency * thrombopenia * long term anticoagulant treatment * pregnancy * allergy to heparin

Keywords: thromboprophylaxis bariatric surgery prevention of venous thromboembolism in bariatric surgery
relation between tumor-draining lymph nodes metastasis pattern and non-small cell lung cancer neoadjuvant immunotherapy effectiveness

Conditions: Lung Cancer

Summary: the goal of this retrospective cohort analysis is to discover the impact of the involvement extent of tumor-draining lymph nodes (tdlns) in patients who received neoadjuvant immunochemotherapy. the main question it aims to answer is the role of tdln in the prediction of treatment effectiveness. researches will compare tumor-draining lymph nodes metastasis (mtdlns) group and non-draining lymph nodes metastasis (mndlns) group to see whether different metastatic patterns of mediastinal lymph nodes can indicate the treatment effectiveness.


Eligibility criteria:
inclusion criteria: * pathologically-confirmed diagnosis of nsclc by pretreatment biopsy * clinically staged as t1-4n0-2m0 * having undergo neoadjuvant chemoimmunotherapy * the agents of immune checkpoint inhibitors (icis) belong to pd-1/l1 inhibitors * having undergo surgery with lymph nodes (lns) dissection * having postoperative pathology reports with evaluation of primary tumor and lns response * having accessible pretreatment and preoperative radiology examinations imaging or reports exclusion criteria: * using pd-1/l1 inhibitors in the phase of clinical trials * the agents of neoadjuvant therapy including angiogenesis inhibitors * having undergone radiotherapy to treat primary tumor or metastatic lns before surgery
efficacy and safety of radiotherapy combined with apatinib mesylate in the treatment of rhabdomyosarcoma in children

Conditions: Childhood Rhabdomyosarcoma

Summary: the purpose of this study is to evaluate the efficacy and safety of radiotherapy combined with apatinib mesylate in the treatment of rhabdomyosarcoma in children.

this study is a interventional study. the target group was 3-18 years old, and the pathological stage was group ii-iv recurrence or distant metastasis. a total of 48 patients were enrolled in this study. the treatment was radiotherapy combined with apatinib. the main outcome measures were orr, dcr , os , quality of life and drug safety. the main safety indicators were vital signs, laboratory indicators, adverse events (ae), and severe adverse events (sae). this study is expected to be enrolled for 6 months.

Eligibility criteria:
inclusion criteria: * patients must be ≥ 3 and ≤ 18 years of age. * the predicted survival period is more than 3 months. * according to recist version 1.1, there is at least one measurable lesion. * postoperative pathological stage was group ii-iv. * patients have not received radiotherapy before, and can accept chemotherapy and surgical treatment. * no other anticancer therapy should be used during radiotherapy. * the main organs are functioning normally, which meets the following criteria: 1. blood routine examination standards should be met: (no blood transfusion within 14 days) a.hb\>90g/l; b.anc\>1.5\*109/l; c.plt\>80\*109/l 2. biochemical tests should meet the following criteria: a. bil \ 50 ml/min * subjects volunteered to participate in this study, patients or legal guardians signed informed consent through patient consent, good compliance, with follow-up. * doctors believe that treatment can benefit patients.

Keywords: radiation therapy rhabdomyosarcoma in children
the efficacy of omega-3 fatty acids in maintaining optimal mental health in elderly people

Conditions: Cognitive Impairment; Depression

Summary: the efficacy of epa-dha supplementation will be assessed in a randomized placebo-controlled trial with cognitive decline and early signs of depression as primary outcome measures.

the efficacy of epa-dha supplementation will be assessed in a randomized placebo-controlled trial with cognitive decline and early signs of depression as primary outcome measures. in this study 300 elderly people will be randomly allocated to one of three treatments. two groups will receive fish oil capsules with different doses epa/dha (a normal dose or a high dose) and the third group will receive placebo capsules. at the start and at the end of the intervention period cognitive function, the occurrence of depression, quality of life, anthropometric values and biochemical indicators will be measured. after completion of the trial a workshop will be organized in which the outcomes of the proposed study will be presented to representatives of several key areas concerning mental health of elderly people.

Eligibility criteria:
inclusion criteria: * men and women * aged 65 years and over * informed consent signed exclusion criteria: * a score of \> 16 on the ces-d (centre for epidemiological studies-depression scale * a score of \< 21 points on mmse (mini-mental state examination) * current or recent (\<4 weeks) use of fish oil supplements or intake of more than 4 times fish as judged by a fish consumption questionnaire * current use of pharmacological antidepressants * current use of dementia (alzheimer) medication * serious liver disease * use of more than 4 glasses of alcohol per day * unable to participate as judged by the responsible medical physician * allergy to fish(oil) * swallowing problems * participation in another clinical trial less than 2 months before the start of the trial or at the same time

Keywords: cognition depression elderly
randomized double-blind trial on safety and efficacy of nanordica advanced antibacterial wound dressing for diabetic foot ulcer

Conditions: Diabetic Foot Ulcer; Diabetic Foot Infection

Summary: this clinical trial evaluates the safety and efficacy of the nanordica advanced antibacterial wound dressing (aawd) in patients suffering from diabetic foot ulcers. at least 170 participants will be randomly allocated to be treated either with aawd or aquacel ag+ extra wound dressing for a 4-week active phase (intervention) followed by an 8-week standard of care period.


Eligibility criteria:
inclusion criteria: * voluntary, written informed consent obtained prior to any study related activities. * males and females aged ≥18 years. * patients suffering dfus for more than 4 weeks with a maximum diameter of 4 cm. * wound infection grades 1 (absent) or 2. * patients willing and able to comply with scheduled visits, laboratory sampling and study procedures. exclusion criteria: * patients receiving systemic or topical antibiotic therapy within 7 days before the enrolment. * patients with any wound with known associated osteomyelitis or positive probe-to-bone test. * patients who have previously been randomized in this clinical trial. * patients who have undergone surgical procedures (e.g., radical debridement, ulcerectomy, surgical offloading, revascularization) or other advanced therapies (e.g. skin substitutes, negative pressure therapy, hyperbaric oxygen therapy) in the same leg than the index wound(s) (i.e., the ones treated and evaluated during the study) within the past four weeks, or are planned to undertake such procedures. * patients suffering cardiac disorders grade nyha iv. * patients suffering hepatic disorders grade child-pugh c. * patients suffering advanced (stage 4) cancer. * patients with ankle-brachial pressure index ≤0.8 or limb peripheral arterial pressure \<60 mmhg. * women of childbearing potential who are pregnant, breast-feeding or not using adequate contraceptive methods.

Keywords: dfu diabetic foot ulcer diabetic foot infection chronic ulcer
sphenopalatine ganglion block for post-dural puncture headache in orthopedic patients

Conditions: Sphenopalatine Ganglion Block; Adrenaline; Post-Dural Puncture Headache; Orthopedic; Randomized Controlled Study

Summary: the aim of this study is to assess the efficacy, onset and duration of analgesia of sphenopalatine ganglion bock (spgb) using lidocaine 4% with adrenaline as a treatment of postoperative post dural puncture headache (pdph) of orthopedic patients after lower limbs surgeries.


Eligibility criteria:
inclusion criteria: * admitted to the orthopedic department * complaining of criteria of severe post-dural puncture headache within 7 days following subarachnoid block used for lower limbs surgeries. * american society of anesthesiologists (asa) physical status i and ii. exclusion criteria: * patient refusal or uncooperative. * patients with uncontrollable hypertension. * patient with known coagulopathy. * patient with nasal septal deviation, polyp, history of nasal bleeding. * patient with allergy to local anesthetics * american society of anesthesiologists physical status\>2.
impact of behavioral feeding intervention on parent-child attachment in young children

Conditions: Pediatric Feeding Disorders

Summary: the primary objective of the proposed study is to determine whether behavioral feeding intervention impacts mother-child attachment in infants and toddlers with feeding problems. the investigators propose the following hypotheses: * behavioral feeding intervention will not significantly impact parent-child attachment. * behavioral feeding intervention will not significantly impact parent-child unstructured play interactions. * severity of feeding problems will decrease after behavioral feeding intervention is implemented. * behavioral feeding intervention will have either no significant effect or a significant positive effect on general child behavior.


Eligibility criteria:
inclusion criteria: caregiver based * mothers * conducts feeding intervention ≥75% of the time at home * understands and speaks english child based * 12-14 or 30-48 months old at initial assessment * clinically significant feeding problem * self-initiates movement * can be left alone in a room for 3 minutes * capable of initiating eye contact
laparoscopic ovarian cystectomy versus aspiration and coagulation in ovarian endometrioma

Conditions: Ovarian Endometrioma

Summary: the aim of this study is to evaluate the impact of laparoscopic ovarian cystectomy versus aspiration and coagulation on ovarian reserve and pelvic pain in cases of ovarian endometrioma.

all patients are presenting with ovarian endometrioma. they are all subjected to informed written consent, full history, general examination, local examination and transvaginal ultrasound. follicular stimulating hormone (fsh), lutenizing hormone (lh), anti mullerian hormone (amh), antral follicular count (afc) and chronic pelvic pain which is assessed by visual analogue scale (vas) of pain scoring system ,all are to be determined before and after laparoscopic surgery (postoperative three months); for two groups (group a) cystectomy and (group b) aspiration and coagulation. histopathological examination was done to the cystectomy group to confirm endometriosis and detect the presence of healthy ovarian tissue in the excised cyst wall.

Eligibility criteria:
inclusion criteria: * female with age group 20-40 years. * female diagnosed by ultrasound with unilateral ovarian endometrioma ≥3cm. exclusion criteria: * previous ovarian surgery. * endocrinological diseases affecting ovarian reserve e.g. diabetes mellitus, hypothyroidism. * polycystic ovary syndrome (pco). * suspicion of ovarian malignancy by ultrasound. * other pelvic pathology e.g. uterine fibroid, pelvic inflammatory disease (pid). * high basal fsh \>10miu/ml (milli-international unit per milliliter).

Keywords: endometrioma laparoscopy ovarian reserve pelvic pain
study of sb-742457 or donepezil versus placebo in subjects with mild-to-moderate alzheimer's disease

Conditions: Alzheimer's Disease

Summary: the study is designed to investigate the efficacy, safety and tolerability of sb-742457 versus placebo in subjects with mild-to-moderate alzheimer's disease. sb-742457 is an experimental treatment which increases the levels of certain chemicals in the brain that are often decreased in patients with alzheimer's disease.


Eligibility criteria:
inclusion criteria: * subjects and their caregivers must provide informed consent prior to study entry. * subjects must have a clinical diagnosis of probable mild-to-moderate alzheimer's disease with a documented 6-month history of ad symptoms * subjects must have a regular caregiver who is willing to attend visits, oversee the subject's compliance with the study and report on the subject's status. * female subjects of child-bearing potential must agree to pregnancy testing and approved form of birth control. exclusion criteria: * diagnosis of possible, probable or definite vascular dementia. * history/evidence of any other cns disorder that could be interpreted as a cause of dementia * history of known or suspected seizures, loss of consciousness or significant head trauma * subjects with ecg, blood pressure and laboratory values outside of protocol criteria are excluded. * subjects with known photosensitivity * subjects with a history of previous exposure to sb-742457, taking agents for which there is a theoretical risk of interaction with sb-742457, or taking medication for alzheimer's disease or centrally acting agents which might impact study outcomes may not participate.

Keywords: alzheimer's disease cognition sb-742457
galectin-3 and placenta accreta

Conditions: Placenta Accreta

Summary: galectins are a family of carbohydrate-binding proteins that have a high affinity to galactosides, its protein portion is located in the nucleus and the cytoplasm with its carbohydrate recognition domain which has high ability to be glycosylated inside or outside the cell. they are expressed by vascular endothelium, immune cells (macrophages, neutrophils, and mast cells), uterus, placenta, cardiac muscle, liver, epithelium of the gastrointestinal tract, and many other tissues. although some galectins have intracellular functions, the majority of them have extracellular activities, which facilitate their contribution to cell adhesion, cell activation, and inflammation. galectin-3 (gal-3) is a unique pentamer of the galectins family and it is involved in both physiological functions; cell growth and differentiation, and pathological conditions; inflammation, fibrosis, and metastasis. regarding pregnancy, gal-3 is proved to participate in angiogenesis, embryo developmental processes, and modulation of maternal immunity.


Eligibility criteria:
inclusion criteria: 1. pregnant women between 28-32 weeks. 2. age between 20-40 years. 3. singleton pregnancy. 4. women with suspicion of placenta accreta 5. cases with mild vaginal bleeding or not having any vaginal bleeding. exclusion criteria: 1. women are known to have any medical disorders. 2. patients with known bleeding disorders or on anticoagulant therapy. 3. patients refuse to participate.